|
ENZ
|
Enzo Biochem, Inc.
|
US
|
NYSE
|
|
EVO
|
Evotec SE
|
US
|
NASDAQ
|
|
EXAI
|
Exscientia Limited
|
US
|
NASDAQ
|
|
FATE
|
Fate Therapeutics, Inc.
|
US
|
NASDAQ
|
|
FBIOP
|
Fortress Biotech, Inc. - 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock
|
US
|
NASDAQ
|
|
FDMT
|
4D Molecular Therapeutics, Inc.
|
US
|
NASDAQ
|
|
FGEN
|
FibroGen, Inc
|
US
|
NASDAQ
|
|
FHTX
|
Foghorn Therapeutics Inc.
|
US
|
NASDAQ
|
|
FRLN
|
Freeline Therapeutics Holdings plc
|
US
|
NASDAQ
|
|
FRTX
|
Fresh Tracks Therapeutics
|
US
|
NASDAQ
|
|
FSTX
|
F-star Therapeutics, Inc.
|
US
|
NASDAQ
|
|
FWBI
|
First Wave BioPharma, Inc.
|
US
|
NASDAQ
|
|
GANX
|
Gain Therapeutics, Inc.
|
US
|
NASDAQ
|
|
GBIO
|
Generation Bio Co.
|
US
|
NASDAQ
|
|
GERM
|
ETFMG Treatments Testing and Advancements ETF
|
US
|
AMEX
|
|
GERN
|
Geron Corporation
|
US
|
NASDAQ
|
|
GMDA
|
Gamida Cell Ltd.
|
US
|
NASDAQ
|
|
GMTX
|
Gemini Therapeutics, Inc.
|
US
|
NASDAQ
|
|
GOSS
|
Gossamer Bio, Inc.
|
US
|
NASDAQ
|
|
GRCL
|
Gracell Biotechnologies Inc.
|
US
|
NASDAQ
|